SciELO - Scientific Electronic Library Online

vol.82 issue3Intraocular pressure in subjects with beta-thalassemia minorIntravitreal and posterior subtenon triamcinolone acetonide for severe acute posterior multifocal placoid pigment epitheliopathy author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links


Arquivos Brasileiros de Oftalmologia

Print version ISSN 0004-2749On-line version ISSN 1678-2925


NUNES, Renata Portella et al. Effectiveness of monthly and fortnightly anti-VEGF treatments for age-related macular degeneration. Arq. Bras. Oftalmol. [online]. 2019, vol.82, n.3, pp.225-232.  Epub Feb 25, 2019. ISSN 0004-2749.


To study the efficacy and safety of treatments with ranibizumab and bevacizumab for exudative age-related macular degeneration.


A parallel randomized clinical trial was conducted to compare the efficacy and safety of three regimens (bevacizumab every month, bevacizumab every 2 weeks, and ranibizumab every month), followed by as-needed retreatments, for 1 year, in previously untreated individuals with age-related macular degeneration. The primary outcome was change in visual acuity and in central macular thickness after 1 year of follow-up. Subjects were assigned randomly to one of the three groups in a 1:1:1 ratio, and investigators and examiners were blinded to the randomization results.


We included 15 patients in each group. After 1 year of follow-up, we found statistically significant improvements in visual acuity and central macular thickness reduction in all groups. However, we found no statistically significant differences between the three groups.


The bi-weekly follow-up was effective and we found no significant differences in efficacy or safety between the treatments with ranibizumab and bevacizumab.

Keywords : Macular degeneration; Retina; Bevacizumab; Ranibizumab; Clinical trial.

        · abstract in Portuguese     · text in English     · English ( pdf )